EUS引导下胆囊引流治疗急性胆囊炎的≥1年随访临床结局:系统评价与荟萃分析
该系统评价与荟萃分析纳入18项研究共701例急性胆囊炎患者,评估EUS引导下胆囊引流(EUS-GBD)随访≥1年的临床结局。技术成功率为95.8%(95%CI 93.9-97.2),临床成功率为94.3%(95%CI 92-96),胆囊炎复发率为4.2%(95%CI 2.8-6.2),再干预率为6%(95%CI 3.6-9.8),因支架梗阻/闭塞需重复内镜率为2.9%(95%CI 1.5-5.6),支架通畅时间为418.8天(95%CI 98.3-739.3)。结论认为EUS-GBD是技术有效且临床持久的治疗方式。
要点
- EUS-GBD技术成功率95.8%、临床成功率94.3%,随访≥1年疗效持久。
- 胆囊炎复发率4.2%、再干预率6%、因支架问题重复内镜率2.9%。
- 支架通畅时间418.8天,1年再入院率19%。
核心结论
- EUS-GBD是急性胆囊炎患者随访超过1年时技术有效且临床持久的治疗方式。
- EUS-GBD总体不良事件发生率低,反映其适用于手术高风险人群。
研究设计与样本
- 系统评价与荟萃分析,检索多个数据库至2024年9月,纳入18项研究共701例急性胆囊炎患者,随访≥1年。
主要发现
- 技术成功率为95.8%(95%CI 93.9-97.2;I2=0)。
- 临床成功率为94.3%(95%CI 92-96;I2=0)。
- 胆囊炎复发率(≥1年)为4.2%(95%CI 2.8-6.2;I2=0)。
- 干预后1年再入院率为19%(95%CI 8.9-36;I2=66),再干预率为6%(95%CI 3.6-9.8;I2=0)。
- 因支架梗阻/闭塞需重复内镜率为2.9%(95%CI 1.5-5.6;I2=0),支架通畅时间为418.8天(95%CI 98.3-739.3;I2=98)。
关键数值与推荐
- 技术成功率95.8%(95%CI 93.9-97.2),临床成功率94.3%(95%CI 92-96)。
- 胆囊炎复发率4.2%(95%CI 2.8-6.2),再干预率6%(95%CI 3.6-9.8)。
- 因支架梗阻/闭塞需重复内镜率2.9%(95%CI 1.5-5.6),支架通畅时间418.8天(95%CI 98.3-739.3)。
- 1年再入院率19%(95%CI 8.9-36)。
临床怎么用
- 对于手术高风险的急性胆囊炎患者,EUS-GBD可作为优于经皮经肝胆囊引流的治疗选择。
- 随访中需关注支架通畅性及胆囊炎复发,尽管再干预率和重复内镜率较低。
局限性
- 支架通畅时间分析异质性高(I2=98%),再入院率分析异质性中等(I2=66%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: EUS-guided gallbladder drainage (EUS-GBD) has emerged as a reliable management option in high-risk surgical patients with acute cholecystitis. Its technical success has been well described in the literature. Guidelines now support the use of EUS-GBD over percutaneous transhepatic gallbladder drainage in this patient population. In this context, we aimed to assess the clinical success of individuals treated with EUS-GBD for acute cholecystitis, with a follow-up period exceeding 1 year. METHODS: Multiple databases were searched for studies looking at EUS-GBD for acute cholecystitis with ≥1 year of follow-up from inception until September 2024. The primary outcome was technical and clinical success. Secondary outcomes included rates of reintervention, stent occlusion, readmission, and adverse events. RESULTS: Eighteen studies met inclusion criteria (n = 701 patients). Technical and clinical success were 95.8% (95% CI, 93.9-97.2; I2 = 0) and 94.3% (95% CI, 92-96; I2 = 0), respectively. Rates of cholecystitis recurrence (≥1 year) were 4.2% (95% CI, 2.8-6.2; I2 = 0). Readmission rates 1 year after intervention were 19% (95% CI, 8.9-36; I2 = 66), whereas the reintervention rate was 6% (95% CI, 3.6-9.8; I2 = 0). The need for repeat endoscopy for stent obstruction/occlusion was 2.9% (95% CI, 1.5%-5.6%; I2 = 0) and stent patency was 418.8 days (95% CI, 98.3-739.3; I2 = 98). CONCLUSIONS: This study demonstrates that EUS-GBD is a technically effective and clinically durable treatment modality for acute cholecystitis, with more than 1-year follow-up duration. The overall low rate of adverse events associated with EUS-GBD reflects its unique ability to care for individuals considered high risk for surgery.
引用
- Canakis A, Tugarinov N, Deliwala S, et al. Clinical outcomes of Endoscopic ultrasound--guided gallbladder drainage in patients with acute cholecystitis with ≥1 year of follow-up: a systematic review and meta-analysis. Gastrointest Endosc. 2025. PMID: 40706905. doi:10.1016/j.gie.2025.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。